Federated Hermes Inc. Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Federated Hermes Inc. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 8.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,145,706 shares of the medical device company’s stock after selling 197,117 shares during the period. Federated Hermes Inc.’s holdings in DexCom were worth $266,261,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KB Financial Partners LLC bought a new stake in DexCom during the 1st quarter valued at $72,000. Bartlett & CO. Wealth Management LLC bought a new stake in DexCom during the 4th quarter valued at $27,000. Valley National Advisers Inc. raised its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. MV Capital Management Inc. increased its holdings in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. Finally, Harbour Investments Inc. increased its holdings in shares of DexCom by 55.6% in the third quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock worth $31,000 after purchasing an additional 120 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.0 %

NASDAQ DXCM traded up $1.33 during mid-day trading on Thursday, reaching $135.19. The stock had a trading volume of 701,939 shares, compared to its average volume of 2,964,936. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The stock has a market cap of $52.12 billion, a PE ratio of 102.18, a price-to-earnings-growth ratio of 2.35 and a beta of 1.20. The company has a fifty day moving average price of $129.20 and a 200 day moving average price of $116.28.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the firm posted $0.34 EPS. The firm’s revenue was up 26.9% on a year-over-year basis. On average, research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on DXCM. UBS Group upped their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Citigroup upped their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Raymond James upped their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $141.40.

Insider Activity

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 20,321 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock valued at $25,530,859 in the last 90 days. Company insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.